Downregulation of CK2 induces apoptosis in cancer cells - A potential approach to cancer therapy

Guixia Wang, Gretchen Unger, Kashif A. Ahmad, Joel W. Slaton, Khalil Ahmed

Research output: Contribution to journalArticlepeer-review


We have previously documented that naked antisense CK2α ODN can potently induce apoptosis in cancer cells in culture and in mouse xenograft human prostate cancer. The effects of the antisense CK2α are related to downregulation of CK2α message and rapid loss of the CK2 from the nuclear compartment. Here we demonstrate that downregulation of CK2 elicited by diverse methods leads to inhibition of cell growth and induction of apoptosis. The various approaches to downregulation of CK2 employed were transfection with kinase-inactive plasmid, use of CK2α siRNA, use of inhibitors of CK2 activity, and use of antisense CK2α ODN packaged in sub-50 nm nanocapsules made from tenascin. In all cases, the downregulation of CK2 is associated with loss in cell survival. We have also described preliminary observations on an approach to targeting CK2 in cancer cells. For this, sub-50 nm tenascin-based nanocapsules bearing the antisense CK2α ODN were employed to test that the antisense is delivered to the cancer cells in vivo. The results provide the first preliminary evidence that such an approach may be feasible for targeting CK2 in cancer cells. Together, our results suggest that CK2 is potentially a highly plausible target for cancer therapy.

Original languageEnglish (US)
Pages (from-to)77-84
Number of pages8
JournalMolecular and Cellular Biochemistry
Issue number1-2
StatePublished - Jun 2005
Externally publishedYes


  • Antisense
  • Apoptosis
  • CK2 inhibitors
  • Cancer
  • Nanocapsules
  • Protein kinase CK2
  • SiRNA
  • Therapy

ASJC Scopus subject areas

  • Molecular Biology
  • Clinical Biochemistry
  • Cell Biology


Dive into the research topics of 'Downregulation of CK2 induces apoptosis in cancer cells - A potential approach to cancer therapy'. Together they form a unique fingerprint.

Cite this